Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Jaguar Health : Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 04:00pm EDT

SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ('Jaguar' or the 'Company'), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc., has agreed in principal to support a U.S.-based University's request to begin an - Institution Initiated Clinical Research Study. The University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in non-HIV patients (the 'Study'). The Study has received approval from the University's Institutional Review Board, and Napo Pharmaceuticals, Inc. is currently negotiating the definitive agreement with the University.

Chronic idiopathic diarrhea is a common complaint of patients presenting to family practitioners, internists and is one of the most common reasons for referral to gastroenterologists. It is estimated that the prevalence of chronic idiopathic diarrhea in developed countries (including the U.S.) is approximately 3-5%. It has a significant negative effect on health-related quality of life and causes a high economic burden on patients and society. The American Gastroenterological Association Burden of Illness study (2012) showed that the estimated annual direct and indirect costs associated with chronic idiopathic diarrhea is up to $524 million per year and $136 million per year, respectively.

The planned open-label pilot study will assess the efficacy of crofelemer during a 28-day treatment period in adult, non-HIV patients with chronic idiopathic diarrhea. The study has an expected duration of one year.

About Crofelemer

Crofelemer, the active pharmaceutical ingredient being tested, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding the expectation that University will perform a pilot study to evaluate the safety and effectiveness of crofelemer for treatment of chronic idiopathic diarrhea in patients. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

Disclaimer

Jaguar Health Inc. published this content on 11 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 July 2019 19:59:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
05:05pHAEMONETICS CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:05pM D C : Richmond American Introduces A New Oro Valley Community
PU
05:05pM D C : Richmond American Debuts Latest Addition to Inspiration Masterplan
PU
05:05pENTERGY : Tate County Wins Excellerator Grant from Entergy Mississippi, Inc.
PU
05:05pWilton Resources Inc. Announces Amendment to Outstanding Warrants
NE
05:04pCISION LTD. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05:03pRAFAEL : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K/A)
AQ
05:03pSANDERSON FARMS INC : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05:03pOCWEN FINANCIAL CORP : Change in Directors or Principal Officers (form 8-K)
AQ
05:03pARLO TECHNOLOGIES : Schedules Second Quarter 2019 Results Conference Call
BU
Latest news "Companies"
Advertisement